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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
c o r r e s p o n d e n c e
A Trial of Hyperglycemic Control in Pediatric Intensive Care
To the Editor: In reporting the results of the 
Control of Hyperglycaemia in Paediatric Inten-
sive Care (CHiP) trial, Macrae et al. (Jan. 9 issue)1 
define “normoglycemia” in children in the inten-
sive care unit (ICU) as a blood glucose level of 
72 to 126 mg per deciliter (4.0 to 7.0 mmol per 
liter), and thus only two thirds of patients in the 
tight-glycemic-control group required insulin. 
The number of days that children were free from 
mechanical ventilation at 30 days was unaffect-
ed, but kidney failure was prevented, the length 
of stay in the hospital was reduced, and the mean 
costs of hospital and community health services 
were lowered by tight glucose control. An earlier 
randomized, controlled trial involving a similar 
patient population targeted healthy fasting blood 
glucose ranges (in infants younger than 1 year, 
50 to 80 mg per deciliter [2.8 to 4.4 mmol per 
liter], and in children 1 year of age or older, 70 to 
100 mg per deciliter [3.9 to 5.6 mmol per liter]). 
That trial, in which all patients required insulin, 
showed reduced morbidity and mortality and, 
subsequently, improved neurocognitive develop-
ment.2,3 In CHiP, most children in the control 
group were spontaneously “normoglycemic” ac-
cording to the authors’ definition (blood glucose 
level, 122 mg per deciliter [6.8 mmol per liter] on 
day 1 and 114 mg per deciliter [6.3 mmol per 
liter] thereafter). Hence, the population at risk 
was diluted by a population not at risk, rendering 
statistical power insufficient. Since tight glucose 
control prevents later complications,4 only the 
more critically ill patients who had more severe 
hyperglycemia and longer stays in the hospital 
— just a fraction of the patients in this study — 
may possibly benefit. The length of hospital stay 
in this study was 5 days shorter with tight glyce-
mic control than with conventional treatment. 
This effect occurred late and was confirmed by 
the analysis of costs in the 12 months after ran-
domization, so that more weight was given to 
patients with longer stays in the hospital.5 Future 
trials of tight glucose control in children in ICUs 
should therefore select only patients “at risk” 
(with hyperglycemia) or increase the sample 
size. Follow-up should not be limited to 30 days.
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To the Editor: After more than a decade of tight 
glycemic control in critically ill patients, whether 
this should be considered a best practice remains 
a controversial subject, mainly in pediatric pa-
tients.1,2 The study by Macrae et al. appears to be 
relevant to this topic, since, in addition to assess-
ment of the financial impact of this treatment, it 
evaluated patients after cardiac surgery and with 
other clinical conditions.
Other studies have suggested that hyperglyce-
mia can result in worse outcomes.1,2 However, a 
recent study has emphasized stress hyperglyce-
mia as an evolutionarily preserved adaptive re-
sponse that increases the survival rate.3
The incidence of hypoglycemia varies in stud-
ies comparing tight glucose control and conven-
tional treatment, mainly because of different 
populations and discrepant glycemic ranges. 
The incidence is higher in studies of tight glu-
cose control1,2 such as the study by Macrae et al. 
Despite the occurrence of seizures in patients in 
this trial, there was no long-term follow-up to 
evaluate the possible sequelae.
Advanced forms of technology such as com-
puterized glucose control4 have paved the way 
for future research and better clinical practices 
to distinguish groups that can really benefit 
from tight glucose control. Which path should 
be followed? New pediatric trials of tight glu-
cose control should be considered, with the use 
of physiological mechanisms to reduce the occur-
rence of adverse effects.
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The Authors Reply: Van den Berghe and Mesot-
ten describe the variability that we noted in our 
article in the four pediatric randomized, con-
trolled trials of glucose control that used insulin; 
these trials involved a total of 3438 patients.1,2 
However, the most marked difference in each 
study is the use of insulin, not the glucose con-
centrations. We therefore question the usefulness 
of further randomized, controlled trials focused 
solely on glucose control.
Van den Berghe and Mesotten suggest that a 
future randomized, controlled trial should focus 
on children with marked hyperglycemia. Our trial 
was not limited to such a population. Rather, it 
answered the practical question of whether a 
glucose level of 72 to 126 mg per deciliter should 
be targeted in children in the pediatric ICU who 
required placement of an arterial catheter, me-
chanical ventilation, and vasoactive drug therapy. 
We concluded that in those circumstances, tight 
glycemic control had no effect on major clinical 
outcomes 30 days after randomization. A sub-
group analysis based on severity-of-illness scores 
to determine the risk of death did not suggest 
that the effect was influenced by risk status, 
though that analysis had low power.
We fully agree that follow-up should not be 
limited to 30 days. We followed our patients for 
up to 1 year. The main benefits of glucose con-
trol were for patients in the non–cardiac-surgery 
subgroup, in whom hospital stay and costs up to 
1 year were reduced.
Other than for a small number of children 
who had traumatic brain injury, our follow-up 
of children who did not remain in or who were 
not readmitted to the ICU on day 30 was only to 
determine how many patients had died and to 
assess for parent-reported use of health services, 
which could be seen as indicators of morbidity. 
We strongly agree that a range of clinically rele-
vant longer-term end points should be part of 
any future randomized, controlled trials involv-
ing children in the pediatric ICU, and we agree 
with Vasques et al. that future applications or 
trials of glucose control should embrace new 
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forms of technology to ensure the safest delivery 
of the intervention.
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Targeted Temperature Management after Cardiac Arrest
To the Editor: Nielsen and coauthors (Dec. 5 is-
sue)1 show the importance of avoiding hyperther-
mia in patients who have had a cardiac arrest. 
However, if the clinical objective is to improve 
the neurologic outcome, it is important to define 
the expected neurologic outcome in individual 
patients. Studies have shown that the severity of 
neuronal lesions is dependent on the delay in ini-
tiation of cooling after reperfusion.2
In the article by Nielsen et al., the studied 
patients had a median return of spontaneous 
circulation of 25 minutes, with a wide interquar-
tile range of 18 to 40 in the hypothermic group 
and 16 to 40 in the normothermic group. In pro-
longed cardiac arrest, we do not expect that a 
reduction of neurologic metabolism by hypother-
mia will have a real effect on already damaged 
structures.
We should not conclude, on the basis of this 
trial, that hypothermia is simply an antihyper-
thermic strategy. Not all cardiac arrests are 
equal in terms of the time to return of sponta-
neous circulation. We should identify the sub-
groups of patients who can benefit from this 
form of therapy.
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To the Editor: Nielsen et al. confirm that fever 
should be avoided in resuscitated patients. How-
ever, several unanswered questions remain be-
fore abandoning therapeutic hypothermia in pa-
tients after cardiac arrest. One key issue is the 
potential benefit of early cooling initiated during 
cardiopulmonary resuscitation (CPR).
Pathophysiological mechanisms1 as well as 
experimental data suggest a benefit of early 
cooling, with intra-arrest cooling clearly superior 
to postresuscitation cooling.2 Thus, when moving 
from very early cooling in the experimental set-
ting to several hours of delay in clinical practice, 
we might miss the time window for the greatest 
effectiveness of hypothermia.3
Transnasal evaporative cooling can be induced 
in field conditions during CPR.4 The method 
induces continuous cooling, primarily to the 
brain, without the hemodynamic side effects 
recently seen with cold saline. Ongoing and fu-
ture studies may add important knowledge to 
this field of research.5
Nielsen et al. permitted a time to initiate 
cooling of 4 hours. We suggest that this time 
window may be crucial to influence outcome.
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